Ebola Survivor and Treating Physician Reflect on 2014 Outbreak
In an interview, Dr. Kent Brantly, who contracted Ebola in 2014, and Dr. Linda Mobula, who treated him, discuss the challenges of the outbreak and the decision to use the experimental drug ZMapp. They reflect on the dangers faced by frontline healthcare workers and the importance of preparedness. The conversation highlights the harrowing realities of the West African epidemic.
Brantly had relocated to Liberia in late 2013 with his family, intending long-term service at ELWA Mission Hospital rather than joining an outbreak response. When Ebola reached the facility, he became medical director of the treatment unit run by Samaritan's Purse, where roughly 20 confirmed patients were cared for—yet only one survived. His own illness began July 23, 2014, with gastrointestinal symptoms and fever; multiple malaria tests came back negative before his condition worsened over roughly ten days.
Mobula arrived within two days of Brantly's symptom onset and observed worsening fever, rash, rapid heartbeat, and altered mental status. The decision to administer ZMapp to Nancy Writebol first—a volunteer hygienist, not a healthcare worker—was based on her older age and perceived vulnerability. Brantly acknowledged uncertainty about how either of them contracted the virus.
This retrospective may reinforce public understanding of the extreme risks frontline medical workers accept during outbreaks, and how scarce experimental treatments force agonizing allocation decisions. It could also shape perceptions of pandemic preparedness, reminding health systems that even trained physicians are vulnerable without robust protective measures. The ongoing DRC outbreak referenced in the piece suggests these lessons remain relevant, potentially influencing how future responders approach experimental therapies and patient prioritization.